Tarsus Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Tarsus Pharmaceuticals, Inc. (TARS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TARS insiders buying or selling?
In the last 12 months, Tarsus Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 24 sales ($19.3M) — net selling of $19.3M. Since October 2020, Trabud has recorded 150 Form 4 filings for TARS: 8 buys ($16.5M) and 142 sells ($65.4M).
Source: SEC EDGAR Form 4
What stands out
- No Tarsus Pharmaceuticals, Inc. insider made an open-market purchase in the last 12 months; the 24 reported open-market sales totaled $19.3M.
Key Statistics (October 2020 – Sep 17, 2026)
Total Form 4 filings
150
SEC EDGAR
Insider filers
19
Insider buys (8)
$16.5M
Insider sells (142)
$65.4M
Insider sentiment
Net sellingNet insider flow of $48.9M in net selling since October 2020, and $19.3M in net selling over the last 12 months.
Recent TARS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | William J Link PHD | Director | Sale | 12.5K | $78.38 | $979.7K | SEC ↗ |
| Sep 9, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 10.0K | $90.56 | $905.6K | SEC ↗ |
| Sep 9, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 14.0K | $87.50 | $1.2M | SEC ↗ |
| Sep 9, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 4.6K | $85.00 | $387.9K | SEC ↗ |
| Sep 3, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 10.0K | $80.06 | $800.6K | SEC ↗ |
| Sep 3, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 11.6K | $77.56 | $898.0K | SEC ↗ |
| Jun 22, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 10.0K | $61.55 | $615.5K | SEC ↗ |
| Jun 17, 2026 | Jeffrey S Farrow | Chief Financial Officer and Chief Strategy Officer | Sale | 14.4K | $60.95 | $877.4K | SEC ↗ |
| Jun 17, 2026 | Katherine Goodrich | Director | Sale | 3.0K | $62.08 | $183.4K | SEC ↗ |
| Jun 17, 2026 | William J Link PHD | Director | Sale | 12.5K | $62.12 | $776.5K | SEC ↗ |
| Mar 24, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 3.0K | $66.75 | $199.5K | SEC ↗ |
| Mar 19, 2026 | Dianne C. Whitfield | Chief Human Resources Officer | Sale | 12.3K | $68.36 | $839.1K | SEC ↗ |
| Mar 19, 2026 | Bryan Wahl | General Counsel | Sale | 12.4K | $68.36 | $850.4K | SEC ↗ |
| Mar 19, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 11.3K | $68.21 | $772.4K | SEC ↗ |
| Mar 19, 2026 | Aziz Mottiwala | Chief Commercial Officer | Sale | 13.1K | $68.36 | $892.5K | SEC ↗ |
| Mar 19, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 1.1K | $68.36 | $78.2K | SEC ↗ |
| Mar 19, 2026 | Jeffrey S Farrow | Chief Financial Officer and Chief Strategy Officer | Sale | 6.4K | $68.36 | $439.6K | SEC ↗ |
| Mar 19, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 34.6K | $68.34 | $2.4M | SEC ↗ |
| Mar 18, 2026 | William J Link PHD | Director | Sale | 12.5K | $68.79 | $859.8K | SEC ↗ |
| Jan 6, 2026 | Dianne C. Whitfield | Chief Human Resources Officer | Sale | 15.6K | $80.67 | $1.3M | SEC ↗ |
| Dec 30, 2025 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 6.0K | $82.51 | $495.1K | SEC ↗ |
| Dec 18, 2025 | Dianne C. Whitfield | Chief Human Resources Officer | Sale | 7.4K | $80.10 | $592.5K | SEC ↗ |
| Dec 17, 2025 | William J Link PHD | Director | Sale | 22.9K | $81.26 | $1.9M | SEC ↗ |
| Dec 17, 2025 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 2.1K | $79.50 | $165.2K | SEC ↗ |
| Sep 26, 2025 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 6.0K | $55.37 | $332.2K | SEC ↗ |
Showing the 25 most recent of 150 Form 4 filings for Tarsus Pharmaceuticals, Inc..
Most active TARS insiders
- Bobak R. Azamian53 filings
- Aziz Mottiwala14 filings
- Dianne C. Whitfield11 filings
- Leonard M. Greenstein11 filings
- Bryan Wahl9 filings
Ask anything about TARS insider activity
Use Trabud's AI agent to query Tarsus Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me TARS CEO purchases this year" or compare it against any other ticker.
Open the AI agentTARS insider trading FAQ
Are Tarsus Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Tarsus Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 24 sales ($19.3M) — net selling of $19.3M. Since October 2020, Trabud has recorded 150 Form 4 filings for TARS: 8 buys ($16.5M) and 142 sells ($65.4M). Over the full record that is net selling of $48.9M.
How many insiders trade TARS stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Tarsus Pharmaceuticals, Inc.. The most recent filing was accepted on Sep 17, 2026.
Where does Trabud get TARS insider trading data?
All TARS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.